Warsaw-based Britenet Med has been awarded a €1 million grant from the European Institute of Innovation and Know-how (EIT) Well being to advance MoodMon, an AI-driven instrument designed to enhance the administration and remedy of power affective issues.
The funding was a part of EIT Well being’s notable Flagship Name, which helps groundbreaking healthcare improvements throughout Europe.
“Our mission with MoodMon is to remodel the administration of power affective issues,” stated Małgorzata Sochacka, MoodMon originator and Product Supervisor at Britenet Med. “By providing a first-in-class resolution that leverages goal knowledge for psychological well being monitoring, we purpose to boost affected person outcomes, scale back healthcare prices, and allow professionals to allocate their time extra successfully. The funding and collaboration alternatives supplied by the EIT Well being Flagship Name devoted to the digital transformation of healthcare are essential steps in bringing MoodMon to extra sufferers and healthcare suppliers throughout Europe. However we don’t cease right here . We’re happy to deepen our collaboration by becoming a member of EIT Well being as a companion. We’re assured that this may allow us to attach with extra distinctive companions throughout Europe, fostering the change of information and experience to boost the remedy of psychological sickness on a worldwide scale.”
Based in 2006, Britenet is a Polish IT firm specialising in consulting and outsourcing companies, in relation to this they’ve developed the AI-based system MoodMon to help remedy for affective issues.
MoodMon presents an progressive method to monitoring situations like melancholy and bipolar dysfunction, which impression an estimated 280 million individuals worldwide. Conventional monitoring strategies depend on self-observation and subjective reporting, which regularly fall brief in figuring out refined adjustments in psychological states.
MoodMon leverages AI to analyse behavioural knowledge collected by way of cell gadgets and wearables, enabling real-time detection of temper adjustments. Its alert system notifies sufferers, psychiatrists, and caregivers promptly, enhancing remedy outcomes.
Medical trials have demonstrated MoodMon’s accuracy, with a sensitivity price of 89.5% and specificity of 98.83%.
The mission is backed by a consortium of establishments throughout Europe, together with Spain’s Fundació de Recerca Clínic Barcelona, Sweden’s Karolinska Institute, and Poland’s Medigent Basis.
The consortium has been established to acquire CE certification, conducting additional medical trials, and exploring the financial advantages MoodMon presents to healthcare methods. The event group additionally goals to create regulatory frameworks that enable AI-driven gadgets like MoodMon to be up to date with out present process full recertification processes.
EIT Well being’s Flagship Name, designed to deal with Europe’s most urgent healthcare challenges, highlights the significance of collaborative innovation.
“Our Flagship Calls are about catalysing collaborations that may make an actual distinction in European healthcare,” stated Joanna Broy, EIT Well being InnoStars Lead for Poland. “MoodMon is a major instance of what will be achieved when progressive firms like Britenet Med come along with main establishments to deal with main well being challenges. This mission showcases the facility of cross-border partnerships in creating options that aren’t solely progressive but in addition scalable and impactful. We’re excited to see how MoodMon will enhance the lives of sufferers with affective issues.”
Along with enhancing affected person care, MoodMon may considerably scale back healthcare prices. The annual direct price of the melancholy remedy ranges from €3k to €5k per affected person and the common direct price of Bipolar Dysfunction remedy quantities to just about €7k per yr per affected person.
MoodMon’s method may alleviate these monetary pressures by enabling early intervention and higher illness administration.
This funding additionally marks Britenet Med’s deeper integration into EIT Well being’s community, positioning the corporate to collaborate with extra European companions. As EIT Well being has supported over 2,500 startups and introduced 113 healthcare options to market, its function in advancing MoodMon is one other step towards progressive options for managing psychological well being.
